Related Experiment Videos
[Follow-up evaluation of metastatic neuroblastoma using high dose [131I-meta]iodobenzylguanidine]
T Klingebiel1, P Reuland, U Feine
1Kinderklinik II, Eberhard-Karls-Universität, Tübingen, FRG.
Insights
High-dose [131I-meta]Iodobenzylguanidine (HD-mIBG) therapy improved imaging for neuroblastoma. Therapeutic scans detected more bone and soft tissue lesions than diagnostic scans, aiding precise diagnosis.
Area of Science:
- Nuclear Medicine
- Pediatric Oncology
Background:
- Neuroblastoma is a pediatric cancer requiring effective diagnostic and therapeutic strategies.
- High-dose radiopharmaceutical therapy is an evolving treatment modality.
Purpose of the Study:
- To evaluate the diagnostic superiority of high-dose [131I-meta]Iodobenzylguanidine (HD-mIBG) scans compared to standard diagnostic scans in children with stage IV neuroblastoma.
- To assess the role of HD-mIBG in lesion detection and diagnosis.
Main Methods:
- Nine children with stage IV neuroblastoma received HD-mIBG therapy (mean dose 699.3 MBq/kg).
- Diagnostic [123I-meta]Iodobenzylguanidine ([123I-m]IBG) scans were performed before and after HD-mIBG treatment.
- Therapeutic HD-mIBG scans were analyzed for lesion detection and diagnostic accuracy.
Main Results:
- HD-mIBG scans were superior for detecting bone lesions in 8/9 children and soft tissue lesions in 4/9 children.
- A more precise diagnosis of the primary tumor was achieved in 1 child.
- Lesions identified on therapeutic scans were further observed in post-therapeutic examinations in 4 children.
Conclusions:
- HD-mIBG imaging offers enhanced detection capabilities for neuroblastoma lesions compared to standard diagnostic scans.
- Therapeutic-dose radioiodine imaging can provide valuable diagnostic information, potentially improving treatment planning and patient management.
Abstract:
Between 1989 and 1990 nine children with neuroblastoma stage IV (according to Evans) have been treated with high-dose [131I-meta]Iodobenzylguanidine (HD-mIBG). The total HD-mIBG dose administered to each child was at mean 699.3 +/- 111 MBq/kg body weight. Prior to (median 28 days) and after (median 50 days) HD-mIBG treatment a diagnostic scan with [123I-meta]Iodobenzylguanidine ([123I-m]IBG) was performed. Scans performed with HD-mIBG were superior to diagnostic scans for the detection of bone lesions in 8/9 children, for the detection of soft tissue lesions in 4/9 children, and for a more precise diagnosis of the primary tumor in 1 child. In 4 children lesions which were primarily identified in the therapeutic scan could be further observed in posttherapeutical examinations.